Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice

Abstract

Responses of subcutaneous tumors to immunotherapy do not necessarily reflect how orthotopic tumors respond. The use of combination immunotherapy stimulating multiple facets of immunity and including cytokine support for T cells can induce effective anti-tumor responses against orthotopic and metastatic tumors.